Sultan S,Irfan SM,Murad S .2016 .Clinico-epidemiological profile of patients with polycythaemia rubra vera - a five year experience from a tertiary care center. Asian Pac J Cancer Prev, 17(3) : 1531-3.
Raedler LA .2014 .Diagnosis and management of polycythemia vera: Proceedings from a multidisciplinary roundtable. Am Health Drug Benefits, 7(7 Suppl 3) : S36-47.
Vardiman JW,Thiele J,Arber DA,Brunning RD,Borowitz MJ,Porwit A .2009 .The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. -03-209262, 114(5) : 937-51.
Pardanani A,Lasho T,Finke C,Hanson C .2007 .Teferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia, 21(9) : 1960-3.
Vannucchi A,Antonioli E,Guglielmelli P,Pardanani A,Teferi A. .2008 .Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia, 22(7) : 1299-307.
Teferi A,Rumi E,Finazzi G,Gisslinger H,Vannucchi A,Rodeghiero F .2013 .Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia, 27(9) : 1874-81.
Szuber N,Mudireddy M,Nicolosi M,Penna D,Vallapureddy RR,Lasho TL .2018 .3023 Mayo Clinic patients with myeloproliferative neoplasms:Risk-stratifiedcomparisonofsurvivalandoutcomesdata among disease subgroups. Mayo Clin Proc, 08(4) : 599-610.
Nawaz R,Zhou Z,Khalid N,Cao D,Liu G,Ren Y .2021 .Incomerelated inequality in distribution of health human resource among districts of Pakistan. BMC Health Serv Res, 21 : 1-15.
Khattak S,Ahmed S,Anwar J,Bozdar M. .2012 .Frequency of janus associated kinase 2 (V617F) mutation in patients of polycythemia vera. J Coll Physicians Surg Pak, 22(2) : 80-3.
Arber DA,Orazi A,Hasserjian R,Thiele J,Borowitz MJ,Le Beau MM .2016 .The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20) : 2391-405.
Panjwani A,Burle VS,Raj R,Thomas S,Gorantla V .2023 .Secondary polycythemia and venous thromboembolism: A systematic review. F1000Res, 12 : 758.
Ip FF,di Pierro I,Brown R,Cunningham I,Handelsman DJ,Liu PY .2010 .Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol, 162(2) : 385-90.
Sung SY,Chang YC,Wu HJ,Lai HC .2022 .Polycythemia-related proliferative ischemic retinopathy managed with smoking cessation: A case report. Int J Environ Res Public Health, 19(13) : .
Haider MZ,Anwer F. Secondary,Polycythemia. StatPearls. Treasure Island F. Secondary .2025 .. StatPearls Publishing, : .
Vainchenker W,Delhommeau F,Constantinescu SN,Bernard OA .2011 .New mutations and pathogenesis of myeloproliferative neoplasms. -02-292102, 118(7) : 1723-35.
Schnittger S,Bacher U,Haferlach C,Geer T,Müller P,Mittermüller J .2009 .Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica, 94(3) : 414-8.
Akram AM,Kausar H,Chaudhary A,Khalid AM,Shahzad MM,Akhtar MW .2018 .Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan. J Cancer, 9(23) : 4341-5.
Sultan S,Irfan SM .2015 .Acquired JAK-2 V617F mutational analysis in Pakistani patients with essential thrombocythemia. Asian Pac J Cancer Prev, 16(16) : 7327-30.
Sultan S,Irfan SM,Murad S .2016 .Clinico-epidemiological profile of patients with polycythaemia rubra vera-A five year experience from a tertiary care center. Asian Pac J Cancer Prev, 17(3) : 1531-3.
Passamonti F,Rumi E,Pungolino E,Malabarba L,Bertazzoni P,Valentini M .2004 .Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med, 117(10) : 755-61.
Hultcrantz M,Björkholm M,Dickman PW,Landgren O,Derolf Å R,Kristinsson SY .2018 .Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: A population-based cohort study. Ann Intern Med, 168(5) : 0028-25.
Barbui T,Vannucchi AM,Carobbio A,Rumi E,Finazzi G,Gisslinger H .2017 .The efect of arterial hypertension on thrombosis in lowrisk polycythemia vera. Am J Hematol, 92(1) : E5-E6.
Landolfi R,Di Gennaro L,Barbui T,De Stefano V,Finazzi G,Marfisi R .2007 .Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 109(6) : 2446-52.
Tremblay D,Mascarenhas J .2020 .Novel therapies in polycythemia vera. Curr Hematol Malig Rep, 15 : 133-40.
Usman M,Bilwani F,Kakepoto G,Adil S,Sajid R,Khurshid M. . .Polycythemia vera and idiopathic erythrocytosis: Comparison of. , : .
Finazzi G,Caruso V,Marchioli R,Capnist G,Chisesi T,Finelli C .2005 .Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 105(7) : 2664-70.
Rambaldi A,Iurlo A,Vannucchi AM,Noble R,von Bubnof N,Guarini A .2020 .Safety and eficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia, 34 : 2234-2237.
Marchioli R,Finazzi G,Specchia G,Cacciola R,Cavazzina R,Cilloni D .2013 .Cardiovascular events and intensity of treatment in polycythemia vera. New Engl J Med, 368(1) : 22-33.
Landolfi R,Marchioli R,Kutti J,Gisslinger H,Tognoni G,Patrono C .2004 .Eficacy and safety of low-dose aspirin in polycythemia vera. New Engl J Med, 350(2) : 114-24.
Kuriakose ET,Gjoni S,Wang YL,Baumann R,Jones AV,Cross NC .2013 .: e135. Haematologica, 98(11) : .
Ferrari A,Carobbio A,Masciulli A,Ghirardi A,Finazzi G,De Stefano V .2019 .Clinical outcomes under hydroxyurea treatment in polycythemia vera: A systematic review and meta-analysis. Haematologica, 104(12) : 2391.
Teferi A,Barbui T. .2023 .Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol, 98(9) : 1465-87.
Antonioli E,Guglielmelli P,Pieri L,Finazzi M,Rumi E,Martinelli V .2012 .Hydroxyurea-related toxicity in 3,411 patients with Ph'- negative MPN. Am J Hematol, 87(5) : 552-4.
Quintás-Cardama A,Kantarjian H,Manshouri T,Luthra R,Estrov Z,Pierce S .2009 .Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol, 23(32) : 5418-24.
Gisslinger H,Zagrijtschuk O,Buxhofer-Ausch V,Thaler J,Schloegl E,Gastl GA .2015 .Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. -04-637280, 126(15) : 1762-9.
Gisslinger H,Klade C,Georgiev P,Krochmalczyk D,GerchevaKyuchukova L,Egyed M .2020 .Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study. Lancet, 3026(19) : 30236-4.
Kiladjian JJ,Winton EF,Talpaz M,Verstovsek S M .2015 .Ruxolitinib for the treatment of patients with polycythemia vera. Expert Rev Hematol, 8(4) : 391-401.
Vannucchi AM,Kiladjian JJ,Griesshammer M,Masszi T,Durrant S,Passamonti F . .Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New Engl J Med2015, 372(5) : 426-35.
Masciulli A,Ferrari A,Carobbio A,Ghirardi A,Barbui T .2020 .Ruxolitinib for the prevention of thrombosis in polycythemia vera: A systematic review and meta-analysis. Blood Adv, 4(2) : 380-6.